Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
acute myeloid leukemia (AML)
Biotech
Foghorn drops sole wholly owned clinical asset after AML failure
Foghorn has finally given up on its only wholly-owned clinical-stage candidate after the troubled cancer drug came up short in a phase 1 trial.
James Waldron
Dec 16, 2024 7:48am
Kyowa Kirin fronts $330M to share rights to Kura's leukemia drug
Nov 21, 2024 9:35am
Molecular Partners tweaks AML trial over 'suboptimal exposure'
Aug 27, 2024 10:00am
Europe leads in cystic fibrosis trials, North America for AML
Apr 16, 2024 5:00pm
Sellas jettisons 2 execs while awaiting ph. 3 cancer vax readout
Mar 8, 2024 10:09am
Kura's leukemia drug works best when tacked onto existing combo
Jan 30, 2024 11:15am
